Oscar fell in its stock-market debut

Hello,

Today in healthcare news: Oscar fell in its stock-market debut, inside DispatchHealth's latest (short!) pitch deck that it used to reach a $1.7 billion valuation, and the data is in on how vaccine work outside clinical trials.

---

Mario Schlosser, CEO and co-founder of Oscar speaks to guests during the TechCrunch Disrupt event in Manhattan, in New York City, NY, U.S. May 15, 2017.

Eduardo Munoz/Reuters

Oscar Health, the original buzzy health-insurance startup, fell 11% in its IPO. We pored over its 215-page filing to find 4 key takeaways.

• Shares of Oscar Health, founded by Joshua Kushner and Mario Schlosser, fell 11% in the company's stock-market debut on Wednesday.
• Its S-1 filing lays out its financials and a dual-class stock structure allowing founders to keep control.
• We pored over the insurer's 215-page filing to find the key takeaways.

Read the full story from Shelby Livingston here>>

---

DispatchHealth clinicians treat patients in their own homes.

Nathan Hindman/DispatchHealth

We got an exclusive look at the presentation that convinced Tiger Global and Humana to invest in a startup's bold vision to do hospitalizations at home at a $1.7 billion valuation

• At-home healthcare startup DispatchHealth said Wednesday it had raised $200 million in Series D funding.
• The round, led by Tiger Global, valued Dispatch at $1.7 billion.
• See the short pitch deck that earned the eight-year-old startup unicorn status.

Read the full story from Blake Dodge and Megan Hernbroth here>>

---

The arrival of coronavirus vaccines means people have started hawking so-called "vaccines" on the Dark Web.

CHRIS JACKSON/POOL/AFP via Getty Images

The data is in: COVID-19 vaccines are proving to be crucial in curbing the pandemic by slashing infections, hospitalizations, and deaths

• The coronavirus vaccines being rolled out are really, really good.
• The first real-world data shows huge drops in transmission, infections, and hospitalizations.
• Vaccines are more than a silver lining to the pandemic - they're our way out.

Read the full story from Andrew Dunn here>>

---

More stories we're reading:

• Dr. Fauci has a stunningly simple way to explain how Johnson & Johnson's COVID-19 vaccine differs from Pfizer's and Moderna's shots (Insider)
• Merck is preparing to launch a new trial for a COVID-19 drug after acquiring it in 2020 (Bloomberg)
• Johnson & Johnson's CEO doesn't want to go back to 'business as usual' after the pandemic and hopes public-private partnerships among pharmaceutical firms continue (Insider)
• Amazon Care's medical provider has filed paperwork in 17 states beyond Washington (Stat News)
• Biden is picking up the work on cancer he started as Obama's VP. His science advisor nominee Eric Lander is expected to lead the effort. (Insider)

---

- Lydia 

Read the original article on Business Insider

from Business Insider https://ift.tt/3e9BH0s